Larimar Therapeutics (LRMR) Price to Earnings (2020 - 2026)

Larimar Therapeutics (LRMR) has reported Price to Earnings for 7 consecutive years, with 9.22 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 38.53% year-over-year to 9.22; the trailing twelve-month figure through Jun 2026 stood at 1.8 (down 5.8% YoY), and the FY2025 full-year result was 1.84, up 32.46% from the prior year.
• Price to Earnings retreated to 9.22 in Q2 2026 per LRMR's latest filing, from 4.95 in the prior quarter.
• Across five years, Price to Earnings topped out at 4.0 in Q2 2022 and bottomed at 28.94 in Q1 2024.
• Historically, Price to Earnings has averaged 12.39 across 5 years, with a median of 9.22 in 2026.
• The sharpest annual moves came in 2023 and 2025: Price to Earnings plunged 252.32% in 2023, then jumped 84.75% in 2025.
• Over 5 years, Price to Earnings stood at 10.19 in 2022, then slumped by 38.41% to 14.11 in 2023, then surged by 44.06% to 7.89 in 2024, then surged by 37.34% to 4.95 in 2025, then sank by 86.52% to 9.22 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 9.22, 4.95, and 5.59 for Q2 2026, Q4 2025, and Q3 2025 respectively.